RSRonald S. Swerdloff

Ronald S. Swerdloff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ronald S. Swerdloff has a total of 165 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Diagnosis of Leydig Cell Dysfunction

    by Ronald S. Swerdloff, Christina Wang

  • Open Access

    Optimizing optical coherence tomography to detect occult spermatozoa in rat testis after induced non-obstructive azoospermia

    by Luyang Yu, Yanhe Lue, Hang Yang, Junze Liu, Carlos Vega, Kevin Ho, Jacob Rajfer, Christina Wang, Ronald Swerdloff, B. Hyle Park

    Although non-obstructive azoospermia (NOA) is characterized by severe impairment of spermatogenesis and a lack of sperm (spermatozoa) in the ejaculate, focal pockets of sperm have been found in 30% to 60% of affected testes.1 Microdissection testicular sperm extraction (micro-TESE)2,3 is the current standard procedure to retrieve occult sperm with a higher sperm retrieval rate and lower degree of postoperative complication than other surgical options such as simple TESE, multiple TESE, biopsy gun needle biopsy, and needle aspiration.4,5 Micro-TESE relies on visual examination through a surgical microscope to identify individual tubules likely to contain sperm based only on cues visible from the outer surface of the tubule, such as diameter and opacity.3 The success heavily relies on the experience of the surgeon. Technological advances capable of providing useful information regarding the entire tubule would allow for more informed intra-surgical extraction of tubules.


  • Testosterontherapie: transdermale Androgene

    by Jonas Čeponis, Fiona Yuen, Ronald S. Swerdloff, Christina Wang

  • Hyper- und hypogonadotroper Hypogonadismus

    by Prativa Rajbhandari, Jerry Sanghun Han, Christina Wang, Ronald Swerdloff

  • Why it is timely to bring a new hormonal male contraceptive to the public – A 35‐year perspective of the authors

    by Ronald S. Swerdloff, William J. Bremner

    This perspective provides an overview of issues needed to bring a testosterone‐progestogen combined transdermal male hormonal contraceptive to the market. Large‐scale phase 2b trials are near completion and a pivotal trial to confirm efficacy and safety has been designed. We believe we are close to accomplishing the steps necessary to bring the first male‐directed effective, safe, and reversible pharmaceutical contraceptive approach to the public. If successful, we believe it will provide a new option for couples to consider in their family planning.


  • Open Access

    In Vitro Generation of Haploid Germ Cells from Human XY and XXY Immature Testes in a 3D Organoid System

    by Guillermo Galdon, Nima Pourhabibi Zarandi, Nicholas A. Deebel, Sue Zhang, Olivia Cornett, Dmitry Lyalin, Mark J. Pettenati, YanHe Lue, Christina Wang, Ronald Swerdloff, et al.

    Increasing survival rates of children following cancer treatment have resulted in a significant population of adult survivors with the common side effect of infertility. Additionally, the availability of genetic testing has identified Klinefelter syndrome (classic 47,XXY) as the cause of future male infertility for a significant number of prepubertal patients. This study explores new spermatogonia stem cell (SSC)-based fertility therapies to meet the needs of these patients. Testicular cells were isolated from cryopreserved human testes tissue stored from XY and XXY prepubertal patients and propagated in a two-dimensional culture. Cells were then incorporated into a 3D human testicular organoid (HTO) system. During a 3-week culture period, HTOs maintained their structure, viability, and metabolic activity. Cell-specific PCR and flow cytometry markers identified undifferentiated spermatogonia, Sertoli, Leydig, and peritubular cells within the HTOs. Testosterone was produced by the HTOs both with and without hCG stimulation. Upregulation of postmeiotic germ cell markers was detected after 23 days in culture. Fluorescence in situ hybridization (FISH) of chromosomes X, Y, and 18 identified haploid cells in the in vitro differentiated HTOs. Thus, 3D HTOs were successfully generated from isolated immature human testicular cells from both euploid (XY) and Klinefelter (XXY) patients, supporting androgen production and germ cell differentiation in vitro.


  • Obesity and Reproductive Dysfunction

    by Ronald Swerdloff, Waleed Butt, Christina Wang

    Obesity can be defined as an excess of body fat, but the metrics to define the term vary in the literature partly because of differences in ethnic/racial groups, and the degree of obesity may relate to the morbidity and mortality created by excess body fat. Excess adipose tissue is a source of inflammatory signals that predispose to increased insulin resistance and cardiovascular risk. This chapter reviews the male and female reproductive systems and identifies mechanisms and magnitudes of dysfunction that can be attributed to or aggravated by obesity. Obesity is associated with polycystic ovarian syndrome (PCOS) in approximately 35%–50% of the women with the syndrome but does not differ sufficiently from non-PCOS women with obesity and can be considered overlapping but separate entities. In both men and women, obesity leads to dysfunction of the hypothalamic–pituitary–gonadal axis. In women, obesity is associated with earlier puberty, dysfunctional menstrual cycles, an increased rate of infertility, and some abnormalities of pregnancy. Much of the literature on female obesity has focused on PCOS. Both obesity and PCOS have strong genetic and epigenetic predispositions. Male reproductive dysfunctions are part of the clinical manifestations of obesity. Hypogonadism, infertility, erectile dysfunction, and prostate disorders are increased in men with obesity compared to men without obesity. Weight loss in individuals with obesity of both genders by lifestyle changes, bariatric surgery, or medical therapies can improve some aspects of obesity-associated reproductive dysfunction and is recommended for multiple health reasons including improvement in reproductive dysfunction.

  • Open Access

    FRI436 Design Of An International Male Contraceptive Efficacy Trial Using A Self-administered Daily Topical Gel Containing Testosterone And Nestorone™

    by Stephanie T Page, John K Amory, Diana Blithe, Regine Sitruk-Ware, Ronald Swerdloff, William Bremner, Peter Liu, Bradley D Anawalt, Arthi Thirumalai, Brian Nguyen, et al.

    Disclosure: S.T. Page: None. Support: Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) through the Contraceptive Development Program’s Contraceptive Clinical Trials Network and by the Population Council. Background: A self-administered male hormonal contraceptive might be very useful to prevent unintended pregnancy. Prior efficacy studies of male hormonal contraceptives have relied on injections or implants of hormones by medical personnel. Transdermal testosterone gels are widely used to treat hypogonadism. Transdermal administration may have utility for male contraception as well; however, no contraceptive efficacy data from the use of a self-administered transdermal male hormonal contraceptive gel are available. Survey data suggests that men are not only interested in male contraception but that a self-administered transdermal gel is desired by many men as an optimal form of contraceptive delivery. A transdermal male contraceptive raises novel considerations regarding compliance with and absorption of the gel in men as well as concern regarding the potential cutaneous transfer of the hormones to the female partner. Previous studies in men have demonstrated that a combined Nestorone-(segesterone acetate) testosterone transdermal gel is well tolerated, and that it safely and effectively suppresses sperm production to contraceptive levels in men who apply it daily. Here we describe the design of an ongoing Phase 2b safety and efficacy trial of this transdermal male contraceptive gel. We discuss the novel aspects and challenges in the design and evaluation of an international transdermal male contraceptive efficacy study that was conducted during a global pandemic. Methods: We are conducting an international, single-arm, open-label study of self-administration of a daily combined Nestorone (segesterone acetate)-testosterone gel for male contraception. Couples are eligible for the study if they are in a committed relationship, at risk for unintended pregnancy and the men have normal spermatogenesis and are in good health. The primary outcome is the rate of pregnancy in couples during the 52-week efficacy phase of the study. Secondary endpoints include the proportion of men suppressing sperm production and entering the efficacy phase, side effects, hormone concentrations in both men and their female partners, sexual function, urinary symptoms, and regimen acceptability for the men and their female partners. ClinicalTrials.gov: NCT03452111. Results: Approximately 460 couples have been enrolled at 17 sites internationally including sites in North and South America, Europe and Africa. The study is now closed to enrollment. Conclusions: We present the design of the first study to examine contraceptive efficacy, side effect profile and acceptability of a self-administered, reversible, male hormonal contraceptive product. Presentation: Friday, June 16, 2023

  • Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines

    by Christina Wang, Maria Cristina Meriggiola, John K. Amory, Christopher L. R. Barratt, Hermann M. Behre, William J. Bremner, Alberto Ferlin, Stanton Honig, Zsolt Kopa, Kirk Lo, et al.

    Backgrounds: Despite a wide spectrum of contraceptive methods for women, the unintended pregnancy rate remains high (45% in the US), with 50% resulting in abortion. Currently, 20% of global contraceptive use is male‐directed, with a wide variation among countries due to limited availability and lack of efficacy. Worldwide studies indicate that >50% of men would opt to use a reversible method, and 90% of women would rely on their partner to use a contraceptive. Additional reasons for novel male contraceptive methods to be available include the increased life expectancy, sharing the reproductive risks among partners, social issues, the lack of pharma industry involvement and the lack of opinion makers advocating for male contraception.Aim: The present guidelines aim to review the status regarding male contraception, the current state of the art to support the clinical practice, recommend minimal requirements for new male contraceptive development and provide and grade updated, evidence‐based recommendations from the European Society of Andrology (EAA) and the American Society of Andrology (ASA).Methods: An expert panel of academicians appointed by the EAA and the ASA generated a consensus guideline according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system.Results: Sixty evidence‐based and graded recommendations were produced on couple‐centered communication, behaviors, barrier methods, semen analysis and contraceptive efficacy, physical agents, surgical methods, actions before initiating male contraception, hormonal methods, non‐hormonal methods, vaccines, and social and ethical considerations.Conclusion: As gender roles transform and gender equity is established in relationships, the male contribution to family planning must be facilitated. Efficient and safe male‐directed methods must be evaluated and introduced into clinical practice, preferably reversible, either hormonal or non‐hormonal. From a future perspective, identifying new hormonal combinations, suitable testicular targets, and emerging vas occlusion methods will produce novel molecules and products for male contraception.